The global market for coronary stents is estimated to be in excess of $7 billion and projected to be growing at 6% per year. With the average age of citizens in developed countries increasing, there is an increased need to provide medical care to the average citizen. As such, an aging population translates into increasing [...]
While reviewing some country-specific data for a research project, I conjectured that there must be a way to conveniently map addresses and display them on a global map. Without the slightest difficulty, I set up and mapped the company appendix (200+ companies) in our coronary stents market report #C245. The mapping data was readily imported [...]
As a follow-up to the Feb. 2 post regarding the settlement of patent disputes between J&J and Boston Scientific, a big driver of that settlement is indeed the level of competitiveness that has come to characterize the coronary stent market. The situation in 2010 is a far cry from the situation in 2003/2004, when the [...]
With Boston Scientific agreeing to settle three outstanding patent suits with Johnson & Johnson’s Cordis division regarding coronary stents for $1.725 billion, the two companies put behind a seven-year fight over the high value market.Â
Both companies hope to take advantage of the opportunity to move on, with Boston Scientific looking to minimize risk in the [...]
With the FDA's approval of Medtronic's Melody Transcatheter Pulmonary Valve and Ensemble Delivery System (see link), another step has been made toward eliminating traditional surgery — at least that's the idea. The ability to implant a valve via a percutaneous procedure advances the art of less invasive intervention in ways akin to laparoscopic surgery, albeit at [...]
In a recent issue of “Circulation: Cardiovascular Interventions”, researchers at the University of Colorado (Aurora) report on the use of rotational angiography to produce three dimensional images of vasculature. When used in interventional cardiology, physicians will be able to visualize clogged arteries, aneurysms or other disease states in order to diagnose them or perform preoperative [...]
The market for coronary stents in Asia and the Pacific region contains principally China (early technology adopters) and Japan (with a longer regulatory approval cycle), which generate roughly 200,000 in stent sales annually. The area is, in the aggregate, the second biggest market for coronary stent sales globally. While China commands much attention due to [...]
The European market for drug-eluting stents is demonstrating its maturity in terms of numbers of competitors, the upward sales growth driven by increasing unit sales rather than premium pricing and other considerations.
Source: MedMarket Diligence, LLC; Report #C245
This illustrates the challenge for manufacturers to differentiate their products and pursue innovations that can command premium pricing, a [...]
Until the advent of coronary stents, patients with cardiovascular blockages had little choice but to either keep a close eye on their disease (“watchful waiting” with or without accompanying pharmaceutical therapy) or undergo coronary artery bypass grafting (CABG). When angioplasty was developed by Andreas Gruentzig in 1977, patients were presented with the option to undergo [...]
Competitors in the market for the treatment of coronary artery disease must face a litany of alternative technologies targeted at this patient caseload. Despite the successes of drug-eluting stents (DES) in producing results that are cost- and outcome-competitive compared to coronary artery bypass grafting, the drive for less invasive alternatives, improved clinical outcomes and other [...]
Contact:
